Commentary

TAG Paper: Observations on Drug Pricing and Innovation in Japan

Full Paper (English): TAG Paper: Observations on Drug Pricing and Innovation in Japan ENG

Full Paper (Japanese): TAG Paper: Observations on Drug Pricing and Innovation in Japan JPN

Key Findings

As the Government of Japan (GOJ) seeks to re-invigorate Japan’s pharmaceutical industry as a sector for innovation and growth, it can make impactful changes to specific pricing policies that will support Japanese patients’ access to the most innovative medicines.

The Asia Group (TAG) has identified two specific pharmaceutical pricing measures that directly undermine the government’s goal of promoting startups and bringing innovative new pharmaceutical products to market. The negative impact of these policies is particularly severe for innovative drugs for rare diseases, for which there are often no alternative treatments:

  1. Strict cost disclosure requirements, especially the “co-factor zero” rule introduced in the cost-based price calculation method in 2022, are effectively canceling out many premiums that were intended to reward innovation and novelty.
  2. Corporate status criteria associated with the Price Maintenance Premium (PMP) system favor companies with a long track record of business in Japan and limit premium benefits for new market entrants.

The intended purpose of these rules is to improve transparency in a product’s total cost and provide incentives for drug launches in Japan. But the two-fold impact of these rules, particularly penalizing new market entrants and foreign entrants, has undermined the intended effect of these measures.

Eliminating these two specific punitive pricing policies represents “low-hanging fruit” for policy change, which can have an immediate impact on the availability of novel drugs, while having a relatively low impact on Japan’s healthcare budget. These changes will stimulate future successful launches and early entrance to Japan, benefitting patients.

Related Posts

Amb. Kurt Tong in CNA: “Trump-Xi-Putin APEC trilateral unprecedented, could unsettle US allies”
United States President Donald Trump, Chinese President Xi Jinping and Russian President Vladimir Putin are expected to hold their first ...
Han Lin in Bloomberg: Futuristic Shenzhen Show Trump the Difficulty of Stopping China
“Shenzhen is no Potemkin showcase. Its technological achievements are real,” said Han Lin, China Country Director at The Asia Group, ...
George Chen in The Straits Times on whether Trump will take a tougher stance on China after his election setback
George Chen, partner and chair of digital practice at the Washington-based consultancy The Asia Group, said Taiwan enjoys strong support ...
Han Lin in The Straits Times: Post Midterm Elections, Asia Faces a More Constrained But No Less Unpredictable Trump
The fundamentals of the US-China relationship will remain largely on the current trajectory, argued Han Shen Lin, the Shanghai-based China ...
Scroll to Top

You Are Applying For:

TAG Paper: Observations on Drug Pricing and Innovation in Japan

Apply Now